Emerald Technology Ventures

Emerald Technology Ventures is a Zurich-based firm with a long history in industrial technology and cleantech investing, and its healthcare exposure reflects a broader push into AI and software adjacent to its industrial heritage. The firm writes $5M-$25M checks across Series A, B, and C and tends to engage as a growth-oriented investor rather than as a pre-seed or seed entry point. Founders pitching Emerald should expect a conversation that draws on the firm’s industrial and technology investing background rather than a pure healthcare specialist diligence.

The declared sub-verticals are AI/ML in healthcare and health IT software, with an explicit AI focus. In practice that means interest in clinical AI platforms, healthcare data infrastructure, software for providers and life-sciences operators, and AI-enabled tooling that scales across European and global enterprise customers. The firm is less active in therapeutics, in consumer wellness, or in hardware-heavy diagnostics that fit traditional medtech timelines. The strongest fits are software companies with credible technical depth, real enterprise traction, and a path to scaling internationally from a European or global base.

Check sizes of $5M-$25M across Series A through Series C position Emerald as a meaningful syndicate participant or co-lead at growth-stage rounds, often joining international syndicates that include US and European specialist healthcare investors. Geographically the firm operates globally with strong European roots, and the Zurich headquarters reflects deep relationships across continental European industrial and technology ecosystems. The firm has cultivated connections with strategic partners and follow-on investors that matter when companies are scaling internationally and preparing for later-stage financings.

The team is built around senior investors with backgrounds spanning industrial technology, cleantech, and AI, with the kind of long tenure and disciplined diligence style that European institutional venture tends to favor. Diligence tends to be substantive on technical depth, financial structure, and the realistic path to scale, with sharp attention to commercial defensibility and unit economics. Founders should expect detailed conversations about technology, customers, and the international growth trajectory.

For founders, the practical read is that Emerald is a credible growth-stage partner for healthcare AI and IT software companies, particularly those with European roots or strong European customer presence. It is less useful for very early-stage founders, for therapeutics, or for those who want a healthcare-only specialist. The engagement style is institutional and technically engaged, with real attention to commercial and strategic questions at the Series A and beyond. Founders building healthcare AI software at growth stage and looking for a European-anchored partner with industrial and technology investing depth will find this firm a thoughtful inclusion in the syndicate.